Direct2Lab Safeguarding Research in Crisis
When global crises hit, delays in science cost lives. Research shows that even a one-month delay in vaccine rollout can lead to over 30,000 additional deaths in a single region. For scientists racing against the clock, continuity is everything. A missed delivery can mean suspended experiments, postponed data, and treatments that arrive too late.
That is why Direct2Lab treats supply assurance as a core social responsibility. In the spring of 2022, this responsibility was tested at one of the world’s most respected pharmaceutical companies: Boehringer Ingelheim.
Keeping Boehringer’s Labs Moving Through Lockdown
During Shanghai’s COVID-19 lockdown, Boehringer Ingelheim’s Taizhou plant urgently needed lab consumables.
Direct2Lab delivered within 72 hours by:
- Coordinating with upstream suppliers.
- Secured licensed cross-city partner.
- Navigating checkpoints and permits.
- Delivered the full shipment by Day 3—ahead of schedule.
This ensured vital experiments continued without interruption.
Protecting Safety With Antigen Kits
As staff safety needs escalated, antigen kit demand rose from 2,000 to 13,000.
Direct2Lab responded by:
- Presenting sourcing and packaging options within 1 hour.
- Mobilizing sales, procurement, logistics, and finance digitally.
- Delivering 13,000 kits in 48 hours.
This enabled Boehringer’s labs to keep research alive during the crisis.
Our Responsibility
Continuity under crisis
Ensuring that under lockdown, Boehringer’s labs did not lose a single critical experiment.
Standing with scientists
Providing the tools and safety measures that allowed research to continue uninterrupted.
Turning urgency into impact
Every uninterrupted day of research is a day closer to new therapies that save lives.
Awarded for Ensuring Research Safety
Direct2Lab earned Boehringer Ingelheim’s “Outstanding Contribution Award for Supply Assurance”, recognizing our role in protecting research continuity and safety during the COVID-19 lockdown.
